Prof Barbara Stähli (University Hospital Zurich, CH) joins us onsite at ESC 23 to outline the findings of the MULTISTARS AMI Trial (NCT03135275).
MULTISTARS AMI aimed to compare the safety and efficacy of two treatment strategies currently performed in clinical practice, immediate complete revascularization versus staged complete revascularization in patients presenting with ST-elevation myocardial infarction (STEMI) and multivessel disease (MVD). Patients randomized to receive staged complete revascularization will have only the culprit lesion treated. 840 participants were enrolled in the trial.
Questions:
-What is the importance of this trial?
-What are the benefits linked with each strategy?
-What was the study design, eligibility criteria and outcome measures?
-What are the key findings presented at ESC?
-How should these findings inform practice?
-What are the remaining questions? What are the next steps?
Recorded on-site at ESC Congress 2023, Amsterdam.
Visit Radcliffe Cardiology:
This content is intended for healthcare professionals only.
Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.
Like us on Facebook:
Follow us on Twitter: